Lorestan University of Medical Sciences, Khorramabad, Iran.
Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mol Biol Rep. 2022 Jan;49(1):605-615. doi: 10.1007/s11033-021-06800-4. Epub 2021 Oct 16.
Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) was first detected in Wuhan, China in December, 2019. The emerging virus causes a respiratory illness, that can trigger a cytokine storm in the body.
Cytokine storm in patient's body is associated with severe forms of disease. It is one of the main complications of coronavirus disease-2019 (COVID-19), in which immune cells play a major role. Studies have shown immune cells in the tumor environment can be effective to induce resistance to chemotherapy in cancer patients.
Therefore, considering the role of immune cells to induce cytokine storm in COVID-19 patients, and their role to cause resistance to chemotherapy, they are effective on disease progression and creation of severe form of disease.
By examining the signaling pathways and inducing resistance to chemotherapy in tumor cells and the cells affect them, it is possible to prevent the occurrence of severe forms of the disease in cancer patients with COVID-19; it is applicable using target therapy and other subsequent treatment strategies.
严重急性呼吸综合征冠状病毒 2(SARS-CoV2)于 2019 年 12 月在中国武汉首次被发现。这种新出现的病毒会引起呼吸道疾病,并在体内引发细胞因子风暴。
患者体内的细胞因子风暴与严重疾病有关。它是 2019 年冠状病毒病(COVID-19)的主要并发症之一,其中免疫细胞起主要作用。研究表明,肿瘤微环境中的免疫细胞可以有效诱导癌症患者对化疗产生耐药性。
因此,鉴于免疫细胞在 COVID-19 患者中引发细胞因子风暴的作用,以及它们导致化疗耐药的作用,它们对疾病进展和严重疾病形式的产生具有重要意义。
通过研究肿瘤细胞及其受影响的细胞中的信号通路以及诱导化疗耐药的机制,可以防止 COVID-19 癌症患者发生严重疾病;这适用于使用靶向治疗和其他后续治疗策略。